logo-loader
CytoDyn

Full interview: CytoDyn CEO says FDA OK to begin Phase 2 to treat colon cancer just 'tip of the iceberg'

CytoDyn Inc (OTCMKTS:CYDY) CEO Dr Nader Pourhassan tells Proactive the FDA has given the greenlight to its Phase 2 protocol for a combination therapy of leronlimab and Regorafenib to treat patients with metastatic colorectal cancer, and this news is just the 'tip of the iceberg' for the biotech.

Pourhassan says the Vancouver, Washington-based biotechnology company said the FDA took around thirty days to review and approve the company to begin its proposed 60-patient clinical investigation.

Quick facts: CytoDyn

Price: $0.39

Market: OTCQB
Market Cap: $146.82 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn named herein, including the promotion by the Company of CytoDyn in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn CEO discusses findings in Yale University report,...

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive that scientists at Yale University's Office of Cooperative Research have recently published a report detailing its successful demonstration of the efficacy of monoclonal antibody targeting of CCR5. Pourhassan says CytoDyn has the...

3 days, 18 hours ago

2 min read